Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories preterm Infant Formula (NEC) Lawsuits Pending in Federal & State Courts (Lawsuits)
Form 10-K Item 3 (Legal Proceedings)
Latest, FY2025
1,760
Period ended Dec 31, 2025
Change on a year earlier
+18.1%
1,490 in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Preterm Infant Formula (NEC) Lawsuits Pending in Federal & State Courts (Lawsuits) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,760 | +18.1% | SEC Filing (0001628280-26-010185) ↗ |
| FY2024 | Dec 31, 2024 | 1,490 | +50.1% | SEC Filing (0001628280-25-007110) ↗ |
| FY2023 | Dec 31, 2023 | 993 | +148.9% | SEC Filing (0001628280-24-005348) ↗ |
| FY2022 | Dec 31, 2022 | 399 | +486.8% | SEC Filing (0001628280-23-004026) ↗ |
| FY2021 | Dec 31, 2021 | 68 | – | SEC Filing (0001104659-22-025141) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Preterm Infant Formula (NEC) Lawsuits Pending in Federal & State Courts (Lawsuits), annual FY2021–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/ped-nec-suits
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.